by Team Small News | Dec 2, 2025 | Divi's Laboratories
The Biosecure Act has created new opportunities for the Indian pharmaceutical industry. The Act, which aims to regulate the use of biotechnology and ensure the safe handling of biological materials, has opened doors for Indian pharma companies to engage in the...
by Team Small News | Nov 18, 2025 | Divi's Laboratories
Divi’s Laboratories, a leading pharmaceutical company, has successfully cleared a US FDA inspection with zero observations. This significant achievement demonstrates the company’s commitment to quality and compliance with regulatory standards. The...
by Team Small News | Nov 16, 2025 | Divi's Laboratories
The US Food and Drug Administration (USFDA) recently conducted an inspection of Unit 1 of Divi’s Laboratories Limited, a leading pharmaceutical company based in India. The inspection was a routine evaluation of the company’s compliance with current Good...
by Team Small News | Jun 30, 2025 | Divi's Laboratories
It appears that you have encountered an error while trying to access the website www.tipranks.com. The error message indicates that your request was blocked by Link11 Web Application Security, which is a security system designed to protect websites from malicious...
by Team Small News | May 24, 2025 | Divi's Laboratories
Divis Laboratories has secured a long-term manufacturing and supply agreement with a global pharmaceutical company. Under the terms of the agreement, Divis will manufacture and supply advanced intermediates to the pharma company, with the details of the commercial...
by Team Small News | Apr 1, 2025 | Aurobindo Pharma, Divi's Laboratories, Pharma, Sun Pharma, Torrent Pharma, Zydus
Citibank has analyzed the potential impact of US tariffs on Indian pharmaceutical companies and has assigned a low probability to such an event. The brokerage firm simulated a 10% tariff scenario and found that companies with a high exposure to US generics, such as...